Cardiovascular Intervention and Therapeutics

, Volume 33, Issue 2, pp 163–168 | Cite as

Comparison of early-phase arterial repair following cobalt-chrome everolimus-eluting stent and slow-release zotarolimus-eluting stent: an angioscopic study

  • Takayuki Ishihara
  • Osamu Iida
  • Masashi Fujita
  • Masaharu Masuda
  • Shin Okamoto
  • Kiyonori Nanto
  • Takashi Kanda
  • Takuya Tsujimura
  • Akihiro Sunaga
  • Masaki Awata
  • Shinsuke Nanto
  • Masaaki Uematsu
Original Article

Abstract

Whether arterial repair following implantation of drug-eluting stents (DES) of the second generation differs among stent types remains unknown. We examined 41 DES placed in 28 patients (age 72 ± 7 years, male 89%) presenting with stable angina pectoris due to de novo lesions in native coronary arteries. Coronary angioscopy was performed 4 ± 1 months after stent implantation. Patients were divided into two groups based on the DES types: 22 cobalt-chrome everolimus-eluting stents (CoCr-EES) in 13 patients and 19 slow-release zotarolimus-eluting stents (R-ZES) in 15 patients. Neointimal coverage (NIC) was graded as: grade 0, stent struts exposed; grade 1, struts bulging into the lumen, although covered; grade 2, struts embedded in the neointima, but translucent; grade 3, struts fully embedded and invisible. NIC was defined as heterogeneous when the NIC grade variation was ≥1. Presence of thrombus was also investigated. Distribution of dominant NIC grade (CoCr-EES: grade 0, 9%; grade 1, 77%; grade 2, 9%; grade 3, 5%; R-ZES: grade 0, 16%; grade 1: 47%; grade 2, 37%; grade 3, 0%, P = 0.38) and heterogeneity of NIC (P = 0.43) were similar between CoCr-EES and R-ZES groups. Existence of thrombus was not significantly different in CoCr-EES and R-ZES (18 versus 42%, P = 0.17). Arterial repair occurred without significant differences between CoCr-EES and R-ZES 4 months after implantation.

Keywords

Angioscopy Arterial repair Drug-eluting stent 

Notes

Acknowledgements

We acknowledge the expertise of Drs. Shota Okuno, Yasuhiro Matsuda and Koji Yanaka in performing cardiac catheterization.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e002230. doi: 10.1161/CIRCINTERVENTIONS.114.002230.CrossRefPubMedGoogle Scholar
  2. 2.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. J Am Coll Cardiol Interv. 2014;7:471–81.CrossRefGoogle Scholar
  3. 3.
    Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134:e123–55. doi: 10.1161/CIR.0000000000000404.CrossRefPubMedGoogle Scholar
  5. 5.
    Sakai S, Mizuno K, Yokoyama S, Tanabe J, Shinada T, Seimiya K, et al. Morphologic changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. J Am Coll Cardiol. 2003;42:1558–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42:680–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. J Am Coll Cardiol Interv. 2009;2:453–8.CrossRefGoogle Scholar
  9. 9.
    Ishihara T, Awata M, Sera F, Fujita M, Watanabe T, Iida O, et al. Arterial repair 4 months after zotarolimus-eluting stent implantation observed on angioscopy. Circ J. 2013;77:1186–92.CrossRefPubMedGoogle Scholar
  10. 10.
    den Heijer P, Foley DP, Hillege HL, Lablanche JM, van Dijk RB, Franzen D, European Working Group on Coronary Angioscopy, et al. The ‘Ermenonville’ classification of observations at coronary angioscopy—evaluation of intra- and inter-observer agreement. European Working Group on Coronary Angioscopy. Eur Heart J. 1994;15:815–22.CrossRefGoogle Scholar
  11. 11.
    Dai K, Matsuoka H, Kawakami H, Sato T, Watanabe K, Nakama Y, et al. Comparison of chronic angioscopic findings of bare metal stents, 1st-generation drug-eluting stents and 2nd-generation drug-eluting stents—Multicenter Study of Intra-Coronary Angioscopy After Stent (MICASA). Circ J. 2016;80:1916–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Nishimoto Y, Matsuo K, Ueda Y, Sugihara R, Hirata A, Murakami A, et al. Angioscopic comparison of resolute and endeavor zotarolimus-eluting stents. Circ J. 2016;80:650–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, et al. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn. 1993;30:104–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J. 2012;163:601–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013;111:1–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Inoue T, Shinke T, Otake H, Nakagawa M, Hariki H, Osue T, et al. Neoatherosclerosis and mural thrombus detection after sirolimus-eluting stent implantation. Circ J. 2014;78:92–100.CrossRefPubMedGoogle Scholar
  18. 18.
    Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: shortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther. 2016;31:196–209.CrossRefPubMedGoogle Scholar
  20. 20.
    Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol. 1998;81:14E−17E. http://www.ajconline.org/. Accessed 31 Oct 2016.

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2017

Authors and Affiliations

  • Takayuki Ishihara
    • 1
  • Osamu Iida
    • 1
  • Masashi Fujita
    • 1
  • Masaharu Masuda
    • 1
  • Shin Okamoto
    • 1
  • Kiyonori Nanto
    • 1
  • Takashi Kanda
    • 1
  • Takuya Tsujimura
    • 1
  • Akihiro Sunaga
    • 1
  • Masaki Awata
    • 2
  • Shinsuke Nanto
    • 3
  • Masaaki Uematsu
    • 1
  1. 1.Cardiovascular Center, Kansai Rosai HospitalAmagasakiJapan
  2. 2.Department of Cardiovascular MedicineOsaka University Graduate School of MedicineSuitaJapan
  3. 3.Nishinomiya Municipal Central HospitalNishinomiyaJapan

Personalised recommendations